Supporting this interpretation, GPC3 and c-MYC showed parallel upregulation in HCLs but not in HepaFH3 or PHHs, consistent with reports that c-MYC can transcriptionally upregulate GPC3 expression, reinforcing their potential combined value as tumor biomarkers [75]. This evidence concerns the gene GPC3 and neoplasm.